Epithelial cell-expressed IL33 is associated with increased tumor immunogenicity by driving CD8+ T cell and dendritic cell type 1 (DC1)-dependent antitumor immunity (Lu et al., 2016; Chen et al., 2020). This evidence concerns the gene IL33 and neoplasm.